ArticleEye (London, England)2021
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world.
Article in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05220085 (Real-life Beovu Experience at UZ Leuven for the Treatment of Exudative Neovascular Age-related Macular Degeneration), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-life Beovu Experience at UZ Leuven for the Treatment of Exudative Neovascular Age-related Macular Degeneration
Who cites it
15 citing papers in PubMed.
- A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with LucentisIndian journal of ophthalmology · 2022Trial
- Current landscape of drug induced retinal vasculitis.Journal of ophthalmic inflammation and infection · 2026Review
- Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.Japanese journal of ophthalmology · 2025Article
- Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2024Article
- Bioengineering of Antibody Fragments: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2023Review
- HIF1A Knockout by Biallelic and Selection-Free CRISPR Gene Editing in Human Primary Endothelial Cells with Ribonucleoprotein Complexes.Biomolecules · 2022Article
- A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer.American journal of ophthalmology case reports · 2022Article
- Progress on the application of growth factor-related drugs in ophthalmology.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.The British journal of ophthalmology · 2022Article
- Bilateral blindness after uneventful brolucizumab injection for macular degeneration.BMC ophthalmology · 2022Article
- Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.Journal of ophthalmology · 2022Article
- [Acute unilateral loss of vision after intravitreal injection of a VEGF inhibitor].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Article
- Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions.American journal of ophthalmology case reports · 2021Article
- Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.PloS one · 2021Article
- Side Effects of Brolucizumab.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.